Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic
Cartography Biosciences, Inc., an oncology company advancing an innovative pipeline of T-cell engaging bispecific and multi-specific antibody therapeutics that target novel and highly specific tumor antigens, today announced the close of a $67 million Series B financing. The funding will help support the advancement of Cartography’s lead program, CBI-1214, into the clinic and the continued acceleration of additional, highly differentiated oncology programs generated from its ATLAS and SUMMIT drug discovery platforms.
Cartography Names Dirk Nagorsen, M.D., as Chief Medical Officer in Expansion of Its Clinical Team
Cartography Biosciences, Inc., an oncology company advancing an innovative pipeline of T-cell engaging bispecific and multi-specific antibody therapeutics that target tumors with high precision, today announced that biopharmaceutical industry and drug development leader Dirk Nagorsen, M.D., joined the company as Chief Medical Officer on August 18th. The company also announced the appointment of Annie Winterhall as Executive Director, Head of Clinical Operations.
Cartography Unveils First Pipeline Program Targeting a Highly-Specific and Emerging Colorectal Cancer Antigen in Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely targets tumors, today announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually.
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors
Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (Nasdaq: KURA) and has served as chairman of its Board of Directors since it was founded in 2014.
Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies Against Novel Targets and Target Pairs
Cartography Biosciences, Inc., announced today that it has entered into a strategic collaboration agreement with Gilead Sciences, Inc., to discover and develop therapies for patients with triple-negative breast cancer (TNBC) and the most common form of non-small cell lung cancer (NSCLC), adenocarcinoma.
